{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:42:12Z","timestamp":1793954532756,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ajo.2012.03.035","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T09:01:16Z","timestamp":1341997276000},"page":"534-541.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Intravitreal Infliximab for Sight-Threatening Relapsing Uveitis in Beh\u00e7et Disease: A Pilot Study in 15 Patients"],"prefix":"10.1016","volume":"154","author":[{"given":"Nikos","family":"Markomichelakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evie","family":"Delicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Masselos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2012.03.035_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000289205","article-title":"The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future","volume":"11","author":"Sfikakis","year":"2010","journal-title":"Curr Dir Autoimmun"},{"issue":"4","key":"10.1016\/j.ajo.2012.03.035_bib2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MAJ.0b013e3180318fbc","article-title":"Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation","volume":"27","author":"Theodossiadis","year":"2007","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2012.03.035_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2004.09.058","article-title":"Regression of neovascular age-related macular degeneration following infliximab therapy","volume":"139","author":"Markomichelakis","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2012.03.035_bib4","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2337\/dc09-2372","article-title":"Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study","volume":"33","author":"Sfikakis","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ajo.2012.03.035_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11926-010-0132-z","article-title":"Beh\u00e7et's syndrome","volume":"12","author":"Yazici","year":"2010","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.ajo.2012.03.035_bib6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ajo.2008.06.019","article-title":"Ocular inflammation in Beh\u00e7et disease: incidence of ocular complications and of loss of visual acuity","volume":"146","author":"Kacmaz","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2012.03.035_bib7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","article-title":"Ocular features of Beh\u00e7et's disease: an international collaborative study","volume":"91","author":"Kitaichi","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"10.1016\/j.ajo.2012.03.035_bib8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2012.03.035_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2007.0015","article-title":"Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Beh\u00e7et disease","volume":"23","author":"Tuncer","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9278","key":"10.1016\/j.ajo.2012.03.035_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ajo.2012.03.035_bib11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion versus corticosteroids for acute panuveitis attacks in Beh\u00e7et's disease: a comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ajo.2012.03.035_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ajo.2012.03.035_bib13","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ajo.2012.03.035_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/jop.2006.0148","article-title":"High-dose infliximab prophylaxis in endotoxin-induced uveitis","volume":"23","author":"Diaz-Llopis","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ajo.2012.03.035_bib15","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/archopht.125.9.1221","article-title":"Intravitreal infliximab and choroidal neovascularization in an animal model","volume":"125","author":"Olson","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2012.03.035_bib16","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1167\/iovs.07-0932","article-title":"A pilot study on ocular safety of intravitreal infliximab in a rabbit model","volume":"49","author":"Giansanti","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.ajo.2012.03.035_bib17","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1167\/iovs.09-3569","article-title":"Intravitreal infliximab clearance in a rabbit model: different sampling methods and assay techniques","volume":"50","author":"Giansanti","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2012.03.035_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00417-008-0967-4","article-title":"Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit","volume":"247","author":"Theodossiadis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2012.03.035_bib19","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1167\/iovs.08-3171","article-title":"Dual role of intravitreous infliximab in experimental choroidal neovascularization: effect on the expression of sulfated glycosaminoglycans","volume":"50","author":"Regatieri","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2012.03.035_bib20","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1177\/112067210901900521","article-title":"Intravitreal infliximab in experimental endotoxin-induced uveitis","volume":"19","author":"Hosseini","year":"2009","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2012.03.035_bib21","first-page":"509","article-title":"Standardization of uveitis nomenclature for reporting clinical data","volume":"140","year":"2005","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ajo.2012.03.035_bib22","series-title":"Uveitis Scoring System","author":"BenEzra","year":"1991"},{"issue":"5","key":"10.1016\/j.ajo.2012.03.035_bib23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et's disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"8697","key":"10.1016\/j.ajo.2012.03.035_bib24","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajo.2012.03.035_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"Giganti","year":"2010","journal-title":"Retina"},{"issue":"4 Suppl 45","key":"10.1016\/j.ajo.2012.03.035_bib26","first-page":"S65","article-title":"Infliximab treatment-induced formation of autoantibodies is common in Beh\u00e7et's disease","volume":"25","author":"Elezoglou","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.ajo.2012.03.035_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0b013e3181cde727","article-title":"More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial","volume":"30","author":"Pulido","year":"2010","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ajo.2012.03.035_bib28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2008.12.004","article-title":"Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration","volume":"147","author":"Theodossiadis","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2012.03.035_bib29","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/IAE.0b013e3181e9f942","article-title":"Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy","volume":"30","author":"Arias","year":"2010","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.ajo.2012.03.035_bib30","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/IAE.0b013e3181d3758a","article-title":"Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis","volume":"30","author":"Farvardin","year":"2010","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ajo.2012.03.035_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/IAE.0b013e3181eac7a6","article-title":"Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2012.03.035_bib32","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/IAE.0b013e3182252a23","article-title":"Toxicity and retinal penetration of infliximab in primates","volume":"32","author":"Melo","year":"2012","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2012.03.035_bib33","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2012.03.035_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clim.2011.09.005","article-title":"Towards the next generation of anti-TNF drugs","volume":"141","author":"Sfikakis","year":"2011","journal-title":"Clin Immunol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939412002486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939412002486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:06:13Z","timestamp":1757595973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939412002486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0002939412002486"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2012.03.035","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717956773.793461359","asserted-by":"object"}]},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal Infliximab for Sight-Threatening Relapsing Uveitis in Beh\u00e7et Disease: A Pilot Study in 15 Patients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2012.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}